But that doesn’t mean people are thrilled about it. According to the company, the generic version of the life-saving drug is on its way to pharmacies across America come next week.  The controversy over price-gouging though, remains largely still in-tact.
Although, the cost-saving option for the drug will largely depend on which insurance a patient has and their eligibility for Mylan ‘s own assistance programs. The insurance part, perhaps, making it much more difficult for certain patients to actually take advantage of the cost-saving EpiPen pack.
